Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on October 17, 2017. The filing reports the closing of a registered direct offering of common stock and warrants. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
- Gross Proceeds: $8.0 million.
- Shares Sold: 3,265,309 shares of common stock.
- Warrants Issued to Investors: Warrants to purchase 1,632,654 shares of common stock.
- Placement Agent Warrants: Warrants to purchase 195,919 shares of common stock.
- Offering Price: $2.45 per unit (one share + one warrant for 0.5 share).
- Warrant Exercise Price (Investors): $2.85 per share.
- Warrant Exercise Price (Placement Agent): $3.06 per share.
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders resulting from the issuance of 3,265,309 new shares and associated warrants. This event was previously disclosed in a Form 8-K filed on October 13, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are detailed in this document beyond the standard disclosure of the capital raise. The filing includes a legal opinion from Hogan Lovells US LLP regarding the legality of the issuance.
Investor Verification Checklist
- Verify the updated share count and diluted share count post-offering.
- Confirm the intended use of the $8.0 million in gross proceeds (not detailed in this specific filing).
- Review the terms of the warrants, specifically the exercise price ($2.85) and expiration date (not provided in this text).
- Check for any underwriting or placement agent fees deducted from the gross proceeds to determine net proceeds.